Anorexia (loss of appetite) is a prevalent and distressing symptom in people with cancer, with limited effective interventions. Medicinal cannabis has shown promise in improving appetite-related symptoms in people with cancer.
Aim:
To assess the efficacy of medicinal cannabis for improving appetite-related symptoms in people with cancer, considering measures and outcomes, interventions and toxicity.
Design:
Systematic review with narrative approach to synthesis and meta-analysis.
Data sources:
Databases (MEDLINE, CINAHL, CENTRAL), websites and trials registries were searched from inception to February 2021. Included studies were randomised controlled trials (RCT) in English peer-reviewed journals comparing medicinal cannabis with placebo and/or another intervention. Study quality was assessed using the Cochrane risk of bias tool.
Results:
Five studies were included that compared medicinal cannabis interventions (dronabinol, nabilone and cannabis extract) either with placebo (n = 4) or megestrol acetate (n = 1). Measures and trial endpoints varied, but efficacy was demonstrated in one trial only, in which dronabinol significantly improved chemosensory perception and other secondary outcomes (taste of food, premeal appetite, proportion of calories consumed as protein) compared with placebo. Cannabis interventions were generally well tolerated across studies, regardless of the product or dose, although the comprehensive measurement of toxicities was limited.
Conclusion:
Evidence from RCTs that medicinal cannabis increases appetite in people with cancer is limited. Measures, outcomes and interventions were variable, and toxicities have not been comprehensively evaluated. Future research should carefully consider biological mechanisms to guide more nuanced selection of endpoints and interventions, including product, dose and administration.
Barajas GalindoDEVidal-CasariegoACalleja-FernándezA, et al. Appetite disorders in cancer patients: impact on nutritional status and quality of life. Appetite2017; 114: 23–27.
2.
EzeokeCCMorleyJE. Pathophysiology of anorexia in the cancer cachexia syndrome. J Cachexia Sarcopenia Muscle2015; 6: 287–302.
KarthikABhatnagarS. Use of cannabis and cannabinoids in palliative care setting. Curr Opin Anaesthesiol2020; 33: 841–546.
5.
SevryuginOKasvisPViganoM, et al. Taste and smell disturbances in cancer patients: a scoping review of available treatments. Support Care Cancer2021; 29: 49–66.
6.
BrueraE. ABC of palliative care: anorexia, cachexia, and nutrition. BMJ1997; 315: 1219–1222.
7.
ChildsDSJatoiA. A hunger for hunger: a review of palliative therapies for cancer-associated anorexia. Ann Palliat Med2019; 8: 50–58.
8.
SaeteawMSanguanboonyaphongPYoodeeJ, et al. Efficacy and safety of pharmacological cachexia interventions: systematic review and network meta-analysis. BMJ Support Palliat Care2021; 11: 75–85.
9.
CurrowDCGlarePLouwS, et al. A randomised, double blind, placebo-controlled trial of megestrol acetate or dexamethasone in treating symptomatic anorexia in people with advanced cancer. Sci Rep2021; 11(1): 2421.
10.
NelsonKWalshDDeeterP, et al. A phase II study of delta-9-tetrahydrocannabinol for appetite stimulation in cancer-associated anorexia. J Palliat Care1994; 10: 14–18.
11.
BrisboisTDde KockIHWatanabeSM, et al. Delta-9-tetrahydrocannabinol may palliate altered chemosensory perception in cancer patients: results of a randomized, double-blind, placebo-controlled pilot trial. Ann Oncol2011; 22: 2086–2093.
12.
RegelsonWButlerJSchulzJ, et al. Delta-9-THC as an effective antidepressant and appetite-stimulating agent in advanced cancer patients. In: BraudeMCSzaraS (eds) The pharmacology of Marihuana. New York, NY: Raven Press, 1976, pp.763–776.
13.
BerryEMMechoulamR. Tetrahydrocannabinol and endocannabinoids in feeding and appetite. Pharmacol Ther2002; 95: 185–190.
14.
CotaDMarsicanoGLutzB, et al. Endogenous cannabinoid system as a modulator of food intake. Int J Obes2003; 27: 289–301.
15.
van ThuijlHKolaBKorbonitsM. Appetite and metabolic effects of ghrelin and cannabinoids: involvement of AMP-activated protein kinase. Vitam Horm2008; 77: 121–148.
16.
KirkhamTC. Cannabinoids and appetite: food craving and food pleasure. Int Rev Psychiatry2009; 21: 163–171.
17.
DonovanKAChangYDOberoi-JassalR, et al. Relationship of cannabis use to patient-reported symptoms in cancer patients seeking supportive/palliative care. J Palliat Med2019; 22: 1191–1195.
18.
YavuzsenTDavisMPWalshD, et al. Systematic review of the treatment of cancer-associated anorexia and weight loss. J Clin Oncol2005; 23: 8500–8511.
19.
DavisMP. Cannabinoids for symptom management and cancer therapy: the evidence. J Natl Compr Canc Netw2016; 14: 915–922.
20.
MückeMWeierMCarterC, et al. Systematic review and meta-analysis of cannabinoids in palliative medicine. J Cachexia Sarcopenia Muscle2018; 9: 220–234.
21.
WangJWangYTongM, et al. Medical cannabinoids for cancer cachexia: a systematic review and meta-analysis. Biomed Res Int2019; 2019: 2864384.
22.
RobertsCAJagerGChristiansenP, et al. Exploring the munchies: an online survey of users’ experiences of cannabis effects on appetite and the development of a cannabinoid Eating Experience Questionnaire. J Psychopharmacol2019; 33(9): 1149–1159.
23.
PageMJMcKenzieJEBossuytPM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Rev Esp Cardiol2021; 74: 790–799.
24.
PirriCBaylissETrotterJ, et al. Nausea still the poor relation in antiemetic therapy? The impact on cancer patients’ quality of life and psychological adjustment of nausea, vomiting and appetite loss, individually and concurrently as part of a symptom cluster. Support Care Cancer2013; 21: 735–748.
25.
BadowskiME. A review of oral cannabinoids and medical marijuana for the treatment of chemotherapy-induced nausea and vomiting: a focus on pharmacokinetic variability and pharmacodynamics. Cancer Chemother Pharmacol2017; 80: 441–449.
26.
OmlinABlumDWiereckyJ, et al. Nutrition impact symptoms in advanced cancer patients: frequency and specific interventions, a case-control study. J Cachexia Sarcopenia Muscle2013; 4: 55–61.
HigginsJPAltmanDGGøtzschePC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ2011; 343: d5928.
29.
HigginsJPGreenS (editors). Cochrane handbook for systematic reviews of interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org.
30.
PopayJRobertsHSowdenA, et al. Guidance on the conduct of narrative synthesis in systematic reviews. A product from the ESRC methods programme Version2006; 1: b92.
31.
JatoiAWindschitlHELoprinziCL, et al. Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study. J Clin Oncol2002; 20: 567–573.
32.
StrasserFLuftnerDPossingerK, et al. Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group. J Clin Oncol2006; 24: 3394–3400.
33.
CôtéMTrudelMWangC, et al. Improving quality of life with nabilone during radiotherapy treatments for head and neck cancers: a randomized double-blind placebo-controlled trial. Ann Otol Rhinol Laryngol2016; 125: 317–324.
34.
TurcottJGDel Rocío Guillen NúñezMFlores-EstradaD, et al. The effect of nabilone on appetite, nutritional status, and quality of life in lung cancer patients: a randomized, double-blind clinical trial. Support Care Cancer2018; 26(9): 3029–3038.
35.
RibaudoJMCellaDHahnEA, et al. Re-validation and shortening of the functional assessment of anorexia/Cachexia Therapy (FAACT) questionnaire. Qual Life Res2000; 9: 1137–1146.
36.
AaronsonNKAhmedzaiSBergmanB, et al. The European Organization for research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst1993; 85: 365–376.
37.
NaitoT. Evaluation of the true endpoint of clinical trials for cancer cachexia. Asia Pac J Oncol Nurs2019; 6: 227–233.
38.
DavisMPDreicerRWalshD, et al. Appetite and cancer-associated anorexia: a review. J Clin Oncol2004; 22: 1510–1517.
39.
SolheimTSBlumDFayersPM, et al. Weight loss, appetite loss and food intake in cancer patients with cancer cachexia: three peas in a pod? – analysis from a multicenter cross sectional study. Acta Oncol2014; 53: 539–546.
40.
BrisboisTDHuttonJLBaracosVE, et al. Taste and smell abnormalities as an independent cause of failure of food intake in patients with advanced cancer-an argument for the application of sensory science. J Palliat Care2006; 22: 111–114.
41.
CardelloAVSchutzHGLesherLL, et al. Development and testing of a labeled magnitude scale of perceived satiety. Appetite2005; 44: 1–13.
42.
CoonCDCookKF. Moving from significance to real-world meaning: methods for interpreting change in clinical outcome assessment scores. Qual Life Res2018; 27: 33–40.
43.
CurrowDLouwSMcCloudP, et al. Regular, sustained-release morphine for chronic breathlessness: a multicentre, double-blind, randomised, placebo-controlled trial. Thorax2020; 75: 50–56.
44.
HopkinsonJB. Psychosocial impact of cancer cachexia. J Cachexia Sarcopenia Muscle2014; 5: 89–94.
45.
JatoiAYamashitaJSloanJA, et al. Does megestrol acetate down-regulate interleukin-6 in patients with cancer-associated anorexia and weight loss? A North Central Cancer Treatment Group investigation. Support Care Cancer2002; 10(1): 71–75.
46.
CotogniPCaccialanzaRPedrazzoliP, et al. Monitoring response to home parenteral nutrition in adult cancer patients. Healthcare2020; 8: 183.
47.
CrawfordJ. What are the criteria for response to cachexia treatment?Ann Palliat Med2019; 8: 43–49.
48.
AtakanZ. Cannabis, a complex plant: different compounds and different effects on individuals. Ther Adv Psychopharmacol2012; 2: 241–254.
49.
McPartlandJMRussoEB. Non-phytocannabinoid constituents of cannabis and herbal synergy. In: PertweeRG (ed.) Handbook of cannabis. Oxford: Oxford University Press, 2014, pp.280–295.
50.
ReuterSEMartinJH. Pharmacokinetics of cannabis in cancer cachexia-anorexia syndrome. Clin Pharmacokinet2016; 55: 807–812.
51.
MorganCJFreemanTPSchaferGL, et al. Cannabidiol attenuates the appetitive effects of Delta 9-tetrahydrocannabinol in humans smoking their chosen cannabis. Neuropsychopharmacology2010; 35: 1879–1885.
52.
CyrCArboledaMFAggarwalSK, et al. Cannabis in palliative care: current challenges and practical recommendations. Ann Palliat Med2018; 7(4): 463–477.
53.
AgurellSHalldinMLindgrenJ, et al. Pharmacokinetics and metabolism of delta 1-tetrahydrocannabinol and other cannabinoids with emphasis on man. Pharmacol Rev1986; 38: 21–43.
54.
BrownDWatsonMSchlossJ. Pharmacological evidence of medicinal cannabis in oncology: a systematic review. Support Care Cancer2019; 27: 3195–3207.
55.
BadowskiMEYanfulPK. Dronabinol oral solution in the management of anorexia and weight loss in AIDS and cancer. Ther Clin Risk Manag2018; 14: 643–651.
56.
MacCallumCARussoEB. Practical considerations in medical cannabis administration and dosing. Eur J Intern Med2018; 49: 12–19.
57.
BottorffJLBissellLJLBalneavesLG, et al. Health effects of using cannabis for therapeutic purposes: a gender analysis of users’ perspectives. Subst Use Misuse2011; 46: 769–780.
58.
RevickiDHaysRDCellaD, et al. Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. J Clin Epidemiol2008; 61(2): 102–109.
59.
O'CathainAThomasKJDrabbleSJ, et al. What can qualitative research do for randomised controlled trials? A systematic mapping review. BMJ Open2013; 3: e002889.
60.
BediGCooperZDHaneyM. Subjective, cognitive and cardiovascular dose-effect profile of nabilone and dronabinol in marijuana smokers. Addict Biol2013; 18: 872–881.
61.
JarrettMMScantleburyJParkerLA. Effect of Δ9-tetrahydrocannabinol on quinine palatability and AM251 on sucrose and quinine palatability using the taste reactivity test. Physiol Behav2007; 90: 425–430.
62.
NahasGG. Hashish in Islam 9th to 18th century. Bull N Y Acad Med1982; 58: 814–831.
63.
AbelEL. Effects of marihuana on the solution of anagrams, memory and appetite. Nature1971; 231: 260–261.
64.
FoltinRWBradyJVFischmanMW. Behavioral analysis of marijuana effects on food intake in humans. Pharmacol Biochem Behav1986; 25: 577–582.
65.
FoltinRWFischmanMWByrneMF. Effects of smoked marijuana on food intake and body weight of humans living in a residential laboratory. Appetite1988; 11: 1–14.
66.
BealJEOlsonRLaubensteinL, et al. Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. J Pain Symptom Manag1995; 10: 89–97.
67.
PlasseTFGorterRWKrasnowSH, et al. Recent clinical experience with dronabinol. Pharmacol Biochem Behav1991; 40: 695–700.
68.
ChvetzoffGTannockIF. Placebo effects in oncology. J Natl Cancer Inst2003; 95: 19–29.
69.
VothEASchwartzRH. Medicinal applications of delta-9-tetrahydrocannabinol and marijuana. Ann Intern Med1997; 126: 791–798.
70.
BealJEOlsonRLefkowitzL, et al. Long-term efficacy and safety of dronabinol for acquired immunodeficiency syndrome-associated anorexia. J Pain Symptom Manag1997; 14: 7–14.
71.
LoprinziCLEllisonNMSchaidDJ, et al. Controlled trial of megestrol acetate for the treatment of cancer anorexia and cachexia. J Natl Cancer Inst1990; 82: 1127–1132.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
